drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00087 | DB00092 | 599 | 58 | [
"DDInter41",
"DDInter40"
] | Alemtuzumab | Alefacept | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Moderate | 1 | [
[
[
599,
24,
58
]
],
[
[
599,
24,
329
],
[
329,
63,
58
]
],
[
[
599,
63,
1172
],
[
1172,
24,
58
]
],
[
[
599,
25,
676
],
[
676,
64,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bleomycin"
],
[
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin and Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ibritumomab tiuxetan a... |
DB01254 | DB14711 | 1,213 | 779 | [
"DDInter484",
"DDInter1680"
] | Dasatinib | Smallpox (Vaccinia) Vaccine, Live | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
1213,
25,
779
]
],
[
[
1213,
64,
1064
],
[
1064,
25,
779
]
],
[
[
1213,
25,
478
],
[
478,
25,
779
]
],
[
[
1213,
63,
147
],
[
147,
... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Clad... | Dasatinib may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Dasatinib may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major l... |
DB00220 | DB01410 | 798 | 423 | [
"DDInter1276",
"DDInter376"
] | Nelfinavir | Ciclesonide (nasal) | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Ciclesonide is an organic molecular entity. | Moderate | 1 | [
[
[
798,
24,
423
]
],
[
[
798,
24,
1573
],
[
1573,
1,
423
]
],
[
[
798,
63,
1351
],
[
1351,
40,
423
]
],
[
[
798,
25,
1486
],
[
1486,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ciclesonide"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
... | Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Ciclesonide
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Ciclesonide (Compound)
Nelfinavir may cause a moderate interaction that could e... |
DB00377 | DB00640 | 1,494 | 1,585 | [
"DDInter1382",
"DDInter31"
] | Palonosetron | Adenosine | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Moderate | 1 | [
[
[
1494,
24,
1585
]
],
[
[
1494,
21,
29355
],
[
29355,
60,
1585
]
],
[
[
1494,
24,
477
],
[
477,
63,
1585
]
],
[
[
1494,
63,
521
],
[
521... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Adenosine"
]
],
[
[
"Palonosetron",
"{u} (Compound) causes {v} (Side Effect)",
"Injection site reaction"
],
[
"Injection site reaction",
... | Palonosetron (Compound) causes Injection site reaction (Side Effect) and Injection site reaction (Side Effect) is caused by Adenosine (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate d... |
DB00662 | DB04948 | 717 | 1,084 | [
"DDInter1873",
"DDInter1083"
] | Trimethobenzamide | Lofexidine | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
717,
24,
1084
]
],
[
[
717,
24,
1617
],
[
1617,
1,
1084
]
],
[
[
717,
63,
1020
],
[
1020,
1,
1084
]
],
[
[
717,
63,
701
],
[
701,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Lofexidine (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine (Compound) resembles Lofe... |
DB08880 | DB12267 | 1,510 | 1,476 | [
"DDInter1771",
"DDInter233"
] | Teriflunomide | Brigatinib | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Major | 2 | [
[
[
1510,
25,
1476
]
],
[
[
1510,
24,
1612
],
[
1612,
23,
1476
]
],
[
[
1510,
64,
168
],
[
168,
23,
1476
]
],
[
[
1510,
64,
629
],
[
629,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fos... | Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Teriflunomide may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may ... |
DB00434 | DB04837 | 13 | 649 | [
"DDInter459",
"DDInter407"
] | Cyproheptadine | Clofedanol | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
13,
24,
649
]
],
[
[
13,
24,
1376
],
[
1376,
24,
649
]
],
[
[
13,
74,
21
],
[
21,
24,
649
]
],
[
[
13,
35,
1405
],
[
1405,
24,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Cyproheptadine (Compound) resembles Amitriptyline (Compound) and Cyproheptadine may cause a modera... |
DB00220 | DB00620 | 798 | 175 | [
"DDInter1276",
"DDInter1855"
] | Nelfinavir | Triamcinolone | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Major | 2 | [
[
[
798,
25,
175
]
],
[
[
798,
24,
1573
],
[
1573,
1,
175
]
],
[
[
798,
25,
617
],
[
617,
40,
175
]
],
[
[
798,
25,
1486
],
[
1486,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednis... | Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Triamcinolone (Compound)
Nelfinavir may lead to a major life threatening interaction when taken with Budesonide and Budesonide (Compound) resembles Triamcinolone (Compound)
Nelfinavi... |
DB00238 | DB11979 | 188 | 1,320 | [
"DDInter1285",
"DDInter625"
] | Nevirapine | Elagolix | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
188,
24,
1320
]
],
[
[
188,
62,
168
],
[
168,
23,
1320
]
],
[
[
188,
23,
608
],
[
608,
23,
1320
]
],
[
[
188,
24,
1297
],
[
1297,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Nevirapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Nevirapine may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Nevirapine may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may c... |
DB01021 | DB11093 | 674 | 636 | [
"DDInter1861",
"DDInter273"
] | Trichlormethiazide | Calcium citrate | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements. | Moderate | 1 | [
[
[
674,
24,
636
]
],
[
[
674,
62,
1572
],
[
1572,
24,
636
]
],
[
[
674,
40,
504
],
[
504,
24,
636
]
],
[
[
674,
1,
1014
],
[
1014,
... | [
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Trichlormethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demecloc... | Trichlormethiazide may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Trichlormethiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazid... |
DB00480 | DB09381 | 1,668 | 192 | [
"DDInter1035",
"DDInter678"
] | Lenalidomide | Esterified estrogens | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of me... | Major | 2 | [
[
[
1668,
25,
192
]
],
[
[
1668,
24,
913
],
[
913,
63,
192
]
],
[
[
1668,
25,
687
],
[
687,
24,
192
]
],
[
[
1668,
24,
129
],
[
129,
... | [
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
... | Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Lenalidomide may lead to a major life threatening interaction when taken with Conestat alfa and Co... |
DB00390 | DB11093 | 1,252 | 636 | [
"DDInter554",
"DDInter273"
] | Digoxin | Calcium citrate | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements. | Moderate | 1 | [
[
[
1252,
24,
636
]
],
[
[
1252,
24,
1572
],
[
1572,
24,
636
]
],
[
[
1252,
1,
1482
],
[
1482,
24,
636
]
],
[
[
1252,
63,
964
],
[
964,
... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[... | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Digoxin (Compound) resembles Digitoxin (Compound) and Digitoxin may cause a moderate interaction that ... |
DB00585 | DB06589 | 1,127 | 1,250 | [
"DDInter1309",
"DDInter1400"
] | Nizatidine | Pazopanib | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
1127,
25,
1250
]
],
[
[
1127,
6,
4973
],
[
4973,
45,
1250
]
],
[
[
1127,
18,
2065
],
[
2065,
46,
1250
]
],
[
[
1127,
7,
2493
],
[
2493... | [
[
[
"Nizatidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Nizatidine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopanib"... | Nizatidine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Pazopanib (Compound)
Nizatidine (Compound) downregulates SRC (Gene) and SRC (Gene) is upregulated by Pazopanib (Compound)
Nizatidine (Compound) upregulates HIST2H2BE (Gene) and HIST2H2BE (Gene) is downregulated by Pazopanib (Compound)
Nizatidine (Com... |
DB00912 | DB08907 | 473 | 1,344 | [
"DDInter1581",
"DDInter280"
] | Repaglinide | Canagliflozin | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
473,
24,
1344
]
],
[
[
473,
24,
549
],
[
549,
1,
1344
]
],
[
[
473,
6,
1829
],
[
1829,
45,
1344
]
],
[
[
473,
21,
28873
],
[
28873,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Repaglinide (Compound) binds ALB (Gene) and ALB (Gene) is bound by Canagliflozin (Compound)
Repaglinide (Compound) causes Pancreatitis (Side Effect) a... |
DB01010 | DB01285 | 61 | 708 | [
"DDInter622",
"DDInter445"
] | Edrophonium | Corticotropin | A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
61,
24,
708
]
],
[
[
61,
63,
751
],
[
751,
24,
708
]
],
[
[
61,
24,
1267
],
[
1267,
63,
708
]
],
[
[
61,
24,
1011
],
[
1011,
64,... | [
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
],... | Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine and Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Amifampr... |
DB00619 | DB11644 | 1,419 | 647 | [
"DDInter909",
"DDInter1737"
] | Imatinib | Tafamidis | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019. | Moderate | 1 | [
[
[
1419,
24,
647
]
],
[
[
1419,
24,
613
],
[
613,
24,
647
]
],
[
[
1419,
63,
663
],
[
663,
24,
647
]
],
[
[
1419,
24,
613
],
[
613,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafamidis"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
],
[
"... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Tafamidis
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrex... |
DB00604 | DB06603 | 1,425 | 39 | [
"DDInter385",
"DDInter1387"
] | Cisapride | Panobinostat | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1425,
25,
39
]
],
[
[
1425,
23,
1247
],
[
1247,
23,
39
]
],
[
[
1425,
24,
479
],
[
479,
23,
39
]
],
[
[
1425,
25,
336
],
[
336,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Cisapride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfam... | Cisapride may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and... |
DB00791 | DB10276 | 132 | 1,624 | [
"DDInter1902",
"DDInter1623"
] | Uracil mustard | Rotavirus vaccine | Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
132,
25,
1624
]
],
[
[
132,
25,
770
],
[
770,
25,
1624
]
],
[
[
132,
63,
58
],
[
58,
25,
1624
]
],
[
[
132,
24,
869
],
[
869,
25... | [
[
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomi... | Uracil mustard may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Rotavirus vaccine
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may lead t... |
DB08871 | DB12141 | 36 | 971 | [
"DDInter666",
"DDInter817"
] | Eribulin | Gilteritinib | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
36,
24,
971
]
],
[
[
36,
62,
1247
],
[
1247,
23,
971
]
],
[
[
36,
63,
112
],
[
112,
23,
971
]
],
[
[
36,
63,
485
],
[
485,
24,
... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Eribulin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Eribulin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole a... |
DB00008 | DB00333 | 491 | 576 | [
"DDInter1407",
"DDInter1166"
] | Peginterferon alfa-2a | Methadone | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Minor | 0 | [
[
[
491,
23,
576
]
],
[
[
491,
24,
112
],
[
112,
62,
576
]
],
[
[
491,
24,
1362
],
[
1362,
63,
576
]
],
[
[
491,
24,
268
],
[
268,
2... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methadone"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronid... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Methadone
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01080 | DB01611 | 855 | 1,487 | [
"DDInter1933",
"DDInter893"
] | Vigabatrin | Hydroxychloroquine | Vigabatrin is an analog of gamma-aminobutyric acid ([GABA]), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms. It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA. Although... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
855,
25,
1487
]
],
[
[
855,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
855,
63,
770
],
[
770,
24,
1487
]
],
[
[
855,
63,
401
],
[
401,
... | [
[
[
"Vigabatrin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Vigabatrin",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v}... | Vigabatrin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Vigabatrin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with... |
DB10429 | DB14762 | 200 | 994 | [
"DDInter282",
"DDInter1602"
] | Candida albicans | Risankizumab | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease... | Moderate | 1 | [
[
[
200,
24,
994
]
],
[
[
200,
63,
4
],
[
4,
24,
994
]
],
[
[
200,
24,
270
],
[
270,
24,
994
]
],
[
[
200,
24,
676
],
[
676,
64,
... | [
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risankizumab"
]
],
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine m... | Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Candida albicans may cause a moderate interaction that could exacerbate di... |
DB01211 | DB06237 | 609 | 438 | [
"DDInter393",
"DDInter141"
] | Clarithromycin | Avanafil | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual ... | Major | 2 | [
[
[
609,
25,
438
]
],
[
[
609,
6,
8374
],
[
8374,
45,
438
]
],
[
[
609,
21,
29093
],
[
29093,
60,
438
]
],
[
[
609,
24,
549
],
[
549,
... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avanafil"
]
],
[
[
"Clarithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"A... | Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Avanafil (Compound)
Clarithromycin (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Avanafil (Compound)
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin a... |
DB00023 | DB01166 | 305 | 477 | [
"DDInter127",
"DDInter379"
] | Asparaginase Escherichia coli | Cilostazol | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
305,
24,
477
]
],
[
[
305,
24,
1247
],
[
1247,
23,
477
]
],
[
[
305,
24,
888
],
[
888,
24,
477
]
],
[
[
305,
24,
936
],
[
936,
6... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbat... |
DB00675 | DB15093 | 888 | 1,654 | [
"DDInter1744",
"DDInter1698"
] | Tamoxifen | Somapacitan | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
888,
24,
1654
]
],
[
[
888,
23,
1135
],
[
1135,
24,
1654
]
],
[
[
888,
25,
351
],
[
351,
24,
1654
]
],
[
[
888,
63,
1010
],
[
1010,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Tamoxifen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Tamoxifen may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a mod... |
DB00280 | DB09330 | 494 | 985 | [
"DDInter575",
"DDInter1352"
] | Disopyramide | Osimertinib | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
494,
25,
985
]
],
[
[
494,
23,
112
],
[
112,
23,
985
]
],
[
[
494,
24,
608
],
[
608,
23,
985
]
],
[
[
494,
24,
1478
],
[
1478,
2... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Disopyramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Disopyramide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and ... |
DB01088 | DB01105 | 714 | 222 | [
"DDInter908",
"DDInter1665"
] | Iloprost | Sibutramine | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
714,
24,
222
]
],
[
[
714,
63,
122
],
[
122,
23,
222
]
],
[
[
714,
25,
802
],
[
802,
63,
222
]
],
[
[
714,
24,
1046
],
[
1046,
6... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
],
[
... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Iloprost may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may cause a moder... |
DB00682 | DB12010 | 126 | 214 | [
"DDInter1951",
"DDInter785"
] | Warfarin | Fostamatinib | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
126,
24,
214
]
],
[
[
126,
63,
723
],
[
723,
24,
214
]
],
[
[
126,
64,
690
],
[
690,
24,
214
]
],
[
[
126,
24,
623
],
[
623,
24,... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Warfarin may lead to a major life threatening interaction when taken with Rifabutin and Rifabutin may cause a mo... |
DB00776 | DB08875 | 1,335 | 1,618 | [
"DDInter1360",
"DDInter262"
] | Oxcarbazepine | Cabozantinib | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
1335,
24,
1618
]
],
[
[
1335,
24,
1135
],
[
1135,
62,
1618
]
],
[
[
1335,
63,
723
],
[
723,
24,
1618
]
],
[
[
1335,
24,
384
],
[
384,
... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
... | Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Ap... |
DB00675 | DB11978 | 888 | 124 | [
"DDInter1744",
"DDInter822"
] | Tamoxifen | Glasdegib | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
888,
24,
124
]
],
[
[
888,
23,
1135
],
[
1135,
23,
124
]
],
[
[
888,
24,
327
],
[
327,
24,
124
]
],
[
[
888,
24,
1032
],
[
1032,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Tamoxifen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"N... | Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Abametapir and Abametapir may ... |
DB00834 | DB11921 | 932 | 1,019 | [
"DDInter1215",
"DDInter492"
] | Mifepristone | Deflazacort | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
932,
25,
1019
]
],
[
[
932,
24,
959
],
[
959,
24,
1019
]
],
[
[
932,
25,
1619
],
[
1619,
63,
1019
]
],
[
[
932,
25,
629
],
[
629,
... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipiz... | Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Mifepristone may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause... |
DB00747 | DB01069 | 1,442 | 401 | [
"DDInter1647",
"DDInter1533"
] | Scopolamine | Promethazine | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1442,
24,
401
]
],
[
[
1442,
24,
146
],
[
146,
24,
401
]
],
[
[
1442,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1442,
6,
4304
],
[
4304,
... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
... | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and D... |
DB00771 | DB00981 | 262 | 1,528 | [
"DDInter397",
"DDInter1462"
] | Clidinium | Physostigmine | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Moderate | 1 | [
[
[
262,
24,
1528
]
],
[
[
262,
24,
1592
],
[
1592,
63,
1528
]
],
[
[
262,
63,
508
],
[
508,
24,
1528
]
],
[
[
262,
24,
543
],
[
543,
... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
],
[
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol and Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazin... |
DB09030 | DB11703 | 840 | 405 | [
"DDInter1945",
"DDInter9"
] | Vorapaxar | Acalabrutinib | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
840,
25,
405
]
],
[
[
840,
63,
383
],
[
383,
24,
405
]
],
[
[
840,
25,
1598
],
[
1598,
63,
405
]
],
[
[
840,
24,
1427
],
[
1427,
... | [
[
[
"Vorapaxar",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
... | Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Vorapaxar may lead to a major life threatening interaction when taken with Tazemetostat an... |
DB00704 | DB01097 | 267 | 1,377 | [
"DDInter1263",
"DDInter1033"
] | Naltrexone | Leflunomide | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
267,
25,
1377
]
],
[
[
267,
18,
8386
],
[
8386,
57,
1377
]
],
[
[
267,
21,
29231
],
[
29231,
60,
1377
]
],
[
[
267,
24,
242
],
[
242,
... | [
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Naltrexone",
"{u} (Compound) downregulates {v} (Gene)",
"MTHFD2"
],
[
"MTHFD2",
"{u} (Gene) is downregulated by {v} (Compound)... | Naltrexone (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Leflunomide (Compound)
Naltrexone (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Leflunomide (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases whe... |
DB06176 | DB08899 | 1,342 | 129 | [
"DDInter1616",
"DDInter649"
] | Romidepsin | Enzalutamide | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1342,
24,
129
]
],
[
[
1342,
63,
918
],
[
918,
1,
129
]
],
[
[
1342,
62,
1247
],
[
1247,
23,
129
]
],
[
[
1342,
24,
230
],
[
230,
... | [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Romidepsin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interacti... |
DB00029 | DB09079 | 25 | 1,496 | [
"DDInter99",
"DDInter1296"
] | Anistreplase | Nintedanib | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Moderate | 1 | [
[
[
25,
24,
1496
]
],
[
[
25,
24,
1317
],
[
1317,
24,
1496
]
],
[
[
25,
25,
365
],
[
365,
24,
1496
]
],
[
[
25,
64,
942
],
[
942,
24... | [
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
],
... | Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Anistreplase may lead to a major life threatening interaction when taken with Dalteparin and Dalteparin ma... |
DB00283 | DB01320 | 701 | 651 | [
"DDInter395",
"DDInter783"
] | Clemastine | Fosphenytoin | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
701,
24,
651
]
],
[
[
701,
63,
362
],
[
362,
1,
651
]
],
[
[
701,
6,
8374
],
[
8374,
45,
651
]
],
[
[
701,
21,
28691
],
[
28691,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Clemastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosphenytoin (Compound)
Clemastine (Compound) causes Somnolence (Side Effect) and Somnol... |
DB00041 | DB00970 | 1,648 | 0 | [
"DDInter38",
"DDInter466"
] | Aldesleukin | Dactinomycin | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | Moderate | 1 | [
[
[
1648,
24,
0
]
],
[
[
1648,
23,
246
],
[
246,
62,
0
]
],
[
[
1648,
23,
1299
],
[
1299,
23,
0
]
],
[
[
1648,
24,
259
],
[
259,
63,... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
]
],
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
],
... | Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Dactinomycin
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and T... |
DB00005 | DB12240 | 1,057 | 110 | [
"DDInter687",
"DDInter1485"
] | Etanercept | Polatuzumab vedotin | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Major | 2 | [
[
[
1057,
25,
110
]
],
[
[
1057,
24,
467
],
[
467,
24,
110
]
],
[
[
1057,
25,
1419
],
[
1419,
24,
110
]
],
[
[
1057,
24,
148
],
[
148,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Etanercept may lead to a major life threatening interaction when taken with Imatinib and Imatinib may... |
DB01035 | DB01249 | 1,401 | 258 | [
"DDInter1524",
"DDInter958"
] | Procainamide | Iodixanol | A derivative of procaine with less CNS action. | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | Moderate | 1 | [
[
[
1401,
24,
258
]
],
[
[
1401,
24,
497
],
[
497,
1,
258
]
],
[
[
1401,
21,
28722
],
[
28722,
60,
258
]
],
[
[
1401,
64,
485
],
[
485,
... | [
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
]
],
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
],
[
... | Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Iohexol and Iohexol (Compound) resembles Iodixanol (Compound)
Procainamide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Iodixanol (Compound)
Procainamide may lead to a major life threatening inte... |
DB00176 | DB06779 | 529 | 365 | [
"DDInter770",
"DDInter470"
] | Fluvoxamine | Dalteparin | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Moderate | 1 | [
[
[
529,
24,
365
]
],
[
[
529,
25,
1039
],
[
1039,
24,
365
]
],
[
[
529,
24,
1018
],
[
1018,
25,
365
]
],
[
[
529,
24,
1468
],
[
1468,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalteparin"
]
],
[
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dex... | Fluvoxamine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopid... |
DB00023 | DB11601 | 305 | 1,270 | [
"DDInter127",
"DDInter1889"
] | Asparaginase Escherichia coli | Tuberculin purified protein derivative | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
305,
24,
1270
]
],
[
[
305,
24,
350
],
[
350,
24,
1270
]
],
[
[
305,
25,
1064
],
[
1064,
24,
1270
]
],
[
[
305,
25,
1259
],
[
1259,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Asparaginase Escherichia coli may lead to a major life threaten... |
DB00679 | DB00981 | 684 | 1,528 | [
"DDInter1796",
"DDInter1462"
] | Thioridazine | Physostigmine | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Moderate | 1 | [
[
[
684,
24,
1528
]
],
[
[
684,
21,
28658
],
[
28658,
60,
1528
]
],
[
[
684,
40,
508
],
[
508,
24,
1528
]
],
[
[
684,
24,
1511
],
[
1511,
... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Thioridazine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is... | Thioridazine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Physostigmine (Compound)
Thioridazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Thioridazine may cause a moderate inte... |
DB00446 | DB06650 | 597 | 1,500 | [
"DDInter351",
"DDInter1324"
] | Chloramphenicol | Ofatumumab | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however... | Moderate | 1 | [
[
[
597,
24,
1500
]
],
[
[
597,
24,
270
],
[
270,
63,
1500
]
],
[
[
597,
24,
869
],
[
869,
24,
1500
]
],
[
[
597,
63,
599
],
[
599,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofatumumab"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Topotecan... |
DB00388 | DB01359 | 1,636 | 729 | [
"DDInter1453",
"DDInter1417"
] | Phenylephrine | Penbutolol | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
1636,
24,
729
]
],
[
[
1636,
63,
461
],
[
461,
1,
729
]
],
[
[
1636,
24,
699
],
[
699,
40,
729
]
],
[
[
1636,
21,
28762
],
[
28762,
... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Phenyl... |
DB00557 | DB09472 | 252 | 1,383 | [
"DDInter895",
"DDInter1693"
] | Hydroxyzine | Sodium sulfate | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
252,
24,
1383
]
],
[
[
252,
24,
609
],
[
609,
24,
1383
]
],
[
[
252,
63,
521
],
[
521,
24,
1383
]
],
[
[
252,
25,
1618
],
[
1618,
... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]... | Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Goserel... |
DB00590 | DB09112 | 1,433 | 1,455 | [
"DDInter592",
"DDInter1306"
] | Doxazosin | Nitrous acid | Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfi... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
1433,
24,
1455
]
],
[
[
1433,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
1433,
1,
1205
],
[
1205,
24,
1455
]
],
[
[
1433,
24,
433
],
[
433,... | [
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[... | Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Doxazosin (Compound) resembles Prazosin (Compound) and Prazosin may cause a moderate interaction that cou... |
DB00981 | DB01148 | 1,528 | 1,128 | [
"DDInter1463",
"DDInter738"
] | Physostigmine (ophthalmic) | Flavoxate | Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Moderate | 1 | [
[
[
1528,
24,
1128
]
],
[
[
1528,
21,
28658
],
[
28658,
60,
1128
]
],
[
[
1528,
24,
537
],
[
537,
63,
1128
]
],
[
[
1528,
63,
1123
],
[
11... | [
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flavoxate"
]
],
[
[
"Physostigmine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is c... | Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Flavoxate
Physostigmine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Flavoxate (Compound)
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Cycliz... |
DB01004 | DB04868 | 563 | 478 | [
"DDInter806",
"DDInter1293"
] | Ganciclovir | Nilotinib | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
563,
24,
478
]
],
[
[
563,
24,
1468
],
[
1468,
63,
478
]
],
[
[
563,
7,
17515
],
[
17515,
46,
478
]
],
[
[
563,
18,
10375
],
[
10375,
... | [
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
... | Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ganciclovir (Compound) upregulates DHDDS (Gene) and DHDDS (Gene) is upregulated by Nilotinib (Compound)
Ganciclovi... |
DB00202 | DB01041 | 190 | 770 | [
"DDInter1716",
"DDInter1789"
] | Succinylcholine | Thalidomide | Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups. It has been widely used for over 50 years, most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and su... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
190,
24,
770
]
],
[
[
190,
21,
28892
],
[
28892,
60,
770
]
],
[
[
190,
24,
1311
],
[
1311,
63,
770
]
],
[
[
190,
24,
61
],
[
61,
... | [
[
[
"Succinylcholine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Succinylcholine",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac arrest"
],
[
"Cardiac arrest",
"{u} ... | Succinylcholine (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Thalidomide (Compound)
Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate dis... |
DB00641 | DB01095 | 467 | 671 | [
"DDInter1675",
"DDInter769"
] | Simvastatin | Fluvastatin | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Moderate | 1 | [
[
[
467,
24,
671
]
],
[
[
467,
24,
788
],
[
788,
40,
671
]
],
[
[
467,
24,
14
],
[
14,
63,
671
]
],
[
[
467,
6,
18701
],
[
18701,
45... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
... | Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Fluvastatin (Compound)
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction... |
DB00978 | DB11126 | 739 | 900 | [
"DDInter1084",
"DDInter276"
] | Lomefloxacin | Calcium gluconate | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets, consequences of hypocalcemia. It can also be taken by mouth but is not recommended by injection into a muscle. Calcium Gluconate Injecti... | Moderate | 1 | [
[
[
739,
24,
900
]
],
[
[
739,
1,
945
],
[
945,
24,
900
]
],
[
[
739,
40,
1176
],
[
1176,
24,
900
]
],
[
[
739,
1,
945
],
[
945,
40,... | [
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may ... | Lomefloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Lomefloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when tak... |
DB06016 | DB08816 | 1,508 | 578 | [
"DDInter300",
"DDInter1802"
] | Cariprazine | Ticagrelor | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
1508,
24,
578
]
],
[
[
1508,
63,
723
],
[
723,
24,
578
]
],
[
[
1508,
24,
868
],
[
868,
63,
578
]
],
[
[
1508,
64,
475
],
[
475,
... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vem... |
DB01208 | DB12332 | 945 | 1,619 | [
"DDInter1705",
"DDInter1626"
] | Sparfloxacin | Rucaparib | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
945,
25,
1619
]
],
[
[
945,
62,
112
],
[
112,
23,
1619
]
],
[
[
945,
25,
1662
],
[
1662,
24,
1619
]
],
[
[
945,
64,
888
],
[
888,
... | [
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Sparfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Sparfloxacin may lead to a major life threatening interaction when taken with Picosulfuric acid and Picosulfu... |
DB00444 | DB08895 | 63 | 976 | [
"DDInter1765",
"DDInter1825"
] | Teniposide | Tofacitinib | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
63,
25,
976
]
],
[
[
63,
23,
307
],
[
307,
23,
976
]
],
[
[
63,
63,
1461
],
[
1461,
23,
976
]
],
[
[
63,
24,
214
],
[
214,
63,
... | [
[
[
"Teniposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Teniposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
... | Teniposide may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E ma... |
DB00880 | DB01278 | 359 | 1,021 | [
"DDInter360",
"DDInter1506"
] | Chlorothiazide | Pramlintide | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
359,
24,
1021
]
],
[
[
359,
24,
708
],
[
708,
63,
1021
]
],
[
[
359,
62,
1507
],
[
1507,
24,
1021
]
],
[
[
359,
63,
891
],
[
891,
... | [
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
... | Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Dicyclom... |
DB06626 | DB14975 | 263 | 988 | [
"DDInter147",
"DDInter1949"
] | Axitinib | Voxelotor | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
263,
24,
988
]
],
[
[
263,
24,
578
],
[
578,
24,
988
]
],
[
[
263,
63,
1250
],
[
1250,
24,
988
]
],
[
[
263,
25,
913
],
[
913,
2... | [
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"... | Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib ma... |
DB00757 | DB09237 | 1,166 | 1,586 | [
"DDInter581",
"DDInter1045"
] | Dolasetron | Levamlodipine | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Major | 2 | [
[
[
1166,
25,
1586
]
],
[
[
1166,
25,
478
],
[
478,
24,
1586
]
],
[
[
1166,
25,
1297
],
[
1297,
63,
1586
]
],
[
[
1166,
64,
1010
],
[
1010... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levamlodipine"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} ... | Dolasetron may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Dolasetron may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may cause a moderate... |
DB00352 | DB00740 | 482 | 424 | [
"DDInter1814",
"DDInter1596"
] | Tioguanine | Riluzole | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi. | Moderate | 1 | [
[
[
482,
24,
424
]
],
[
[
482,
21,
28868
],
[
28868,
60,
424
]
],
[
[
482,
63,
305
],
[
305,
24,
424
]
],
[
[
482,
24,
322
],
[
322,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riluzole"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Stomatitis"
],
[
"Stomatitis",
"{u} (Side Effect) is caus... | Tioguanine (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Riluzole (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exace... |
DB00289 | DB00675 | 847 | 888 | [
"DDInter132",
"DDInter1744"
] | Atomoxetine | Tamoxifen | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
847,
24,
888
]
],
[
[
847,
1,
1661
],
[
1661,
40,
888
]
],
[
[
847,
24,
543
],
[
543,
63,
888
]
],
[
[
847,
40,
649
],
[
649,
1,... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Phenoxybenzamine"
],
[
"Phenoxybenzamine",
"{u} (Compo... | Atomoxetine (Compound) resembles Phenoxybenzamine (Compound) and Phenoxybenzamine (Compound) resembles Tamoxifen (Compound)
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00539 | DB01764 | 11 | 805 | [
"DDInter1837",
"DDInter469"
] | Toremifene | Dalfopristin | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Moderate | 1 | [
[
[
11,
24,
805
]
],
[
[
11,
6,
8374
],
[
8374,
45,
805
]
],
[
[
11,
63,
1101
],
[
1101,
23,
805
]
],
[
[
11,
24,
283
],
[
283,
62,
... | [
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dalfopristin
Toremifene may c... |
DB00055 | DB00461 | 834 | 598 | [
"DDInter605",
"DDInter1254"
] | Drotrecogin alfa | Nabumetone | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Major | 2 | [
[
[
834,
25,
598
]
],
[
[
834,
64,
1271
],
[
1271,
24,
598
]
],
[
[
834,
25,
366
],
[
366,
24,
598
]
],
[
[
834,
25,
1512
],
[
1512,
... | [
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nabumetone"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alteplase"
],
[
"Alteplase",
... | Drotrecogin alfa may lead to a major life threatening interaction when taken with Alteplase and Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone
Drotrecogin alfa may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a... |
DB09080 | DB12245 | 144 | 823 | [
"DDInter1331",
"DDInter1863"
] | Olodaterol | Triclabendazole | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
144,
24,
823
]
],
[
[
144,
62,
1247
],
[
1247,
23,
823
]
],
[
[
144,
24,
1612
],
[
1612,
24,
823
]
],
[
[
144,
63,
1010
],
[
1010,
... | [
[
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Olodaterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],... | Olodaterol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Fostemsa... |
DB00307 | DB09291 | 1,101 | 741 | [
"DDInter202",
"DDInter1615"
] | Bexarotene | Rolapitant | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
1101,
24,
741
]
],
[
[
1101,
24,
1135
],
[
1135,
23,
741
]
],
[
[
1101,
24,
159
],
[
159,
63,
741
]
],
[
[
1101,
24,
1671
],
[
1671,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotre... |
DB00532 | DB01024 | 208 | 1,096 | [
"DDInter1152",
"DDInter1252"
] | Mephenytoin | Mycophenolic acid | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Minor | 0 | [
[
[
208,
23,
1096
]
],
[
[
208,
24,
387
],
[
387,
23,
1096
]
],
[
[
208,
63,
1031
],
[
1031,
23,
1096
]
],
[
[
208,
24,
609
],
[
609,
... | [
[
[
"Mephenytoin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acyclovir"
],
... | Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Acyclovir and Acyclovir may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and... |
DB01172 | DB01416 | 416 | 1,024 | [
"DDInter1004",
"DDInter326"
] | Kanamycin | Cefpodoxime | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime. | Moderate | 1 | [
[
[
416,
24,
1024
]
],
[
[
416,
24,
1453
],
[
1453,
1,
1024
]
],
[
[
416,
63,
149
],
[
149,
40,
1024
]
],
[
[
416,
63,
315
],
[
315,
... | [
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefpodoxime"
]
],
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftriaxone"
],
[
... | Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Ceftriaxone and Ceftriaxone (Compound) resembles Cefpodoxime (Compound)
Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Ceftazidime and Ceftazidime (Compound) resembles Cefpodoxime (Compou... |
DB00227 | DB06372 | 1,463 | 259 | [
"DDInter1098",
"DDInter1594"
] | Lovastatin | Rilonacept | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
1463,
24,
259
]
],
[
[
1463,
24,
1619
],
[
1619,
63,
259
]
],
[
[
1463,
24,
478
],
[
478,
24,
259
]
],
[
[
1463,
63,
168
],
[
168,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib... |
DB00227 | DB01211 | 1,463 | 609 | [
"DDInter1098",
"DDInter393"
] | Lovastatin | Clarithromycin | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Major | 2 | [
[
[
1463,
25,
609
]
],
[
[
1463,
6,
4973
],
[
4973,
45,
609
]
],
[
[
1463,
7,
3466
],
[
3466,
46,
609
]
],
[
[
1463,
18,
4360
],
[
4360,
... | [
[
[
"Lovastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
]
],
[
[
"Lovastatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Clari... | Lovastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Lovastatin (Compound) upregulates CCNA1 (Gene) and CCNA1 (Gene) is upregulated by Clarithromycin (Compound)
Lovastatin (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Clarithromycin (Compound)
Lova... |
DB00193 | DB00835 | 534 | 100 | [
"DDInter1841",
"DDInter245"
] | Tramadol | Brompheniramine | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
534,
24,
100
]
],
[
[
534,
24,
832
],
[
832,
24,
100
]
],
[
[
534,
24,
28
],
[
28,
40,
100
]
],
[
[
534,
24,
649
],
[
649,
63,
... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
... | Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl an... |
DB00468 | DB01208 | 1,424 | 945 | [
"DDInter1557",
"DDInter1705"
] | Quinine | Sparfloxacin | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Major | 2 | [
[
[
1424,
25,
945
]
],
[
[
1424,
24,
739
],
[
739,
1,
945
]
],
[
[
1424,
64,
1176
],
[
1176,
1,
945
]
],
[
[
1424,
25,
246
],
[
246,
... | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Quinine may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (Compound)
Quinine m... |
DB00651 | DB01337 | 746 | 1,579 | [
"DDInter613",
"DDInter1385"
] | Dyphylline | Pancuronium | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release. | Moderate | 1 | [
[
[
746,
24,
1579
]
],
[
[
746,
24,
1610
],
[
1610,
1,
1579
]
],
[
[
746,
21,
28717
],
[
28717,
60,
1579
]
],
[
[
746,
40,
1031
],
[
1031,... | [
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pancuronium"
]
],
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
],
[
... | Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium and Rocuronium (Compound) resembles Pancuronium (Compound)
Dyphylline (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Pancuronium (Compound)
Dyphylline (Compound) resembles Theophylline... |
DB04868 | DB08913 | 478 | 1,186 | [
"DDInter1293",
"DDInter1561"
] | Nilotinib | Radium Ra 223 dichloride | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
478,
24,
1186
]
],
[
[
478,
21,
28722
],
[
28722,
60,
1186
]
],
[
[
478,
63,
134
],
[
134,
24,
1186
]
],
[
[
478,
25,
1491
],
[
1491,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Nilotinib",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) i... | Nilotinib (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB05294 | DB11760 | 1,069 | 119 | [
"DDInter1917",
"DDInter1742"
] | Vandetanib | Talazoparib | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
1069,
24,
119
]
],
[
[
1069,
25,
985
],
[
985,
24,
119
]
],
[
[
1069,
64,
932
],
[
932,
24,
119
]
],
[
[
1069,
25,
1293
],
[
1293,
... | [
[
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimerti... | Vandetanib may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Vandetanib may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may cause a modera... |
DB08871 | DB09083 | 36 | 880 | [
"DDInter666",
"DDInter996"
] | Eribulin | Ivabradine | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
36,
25,
880
]
],
[
[
36,
63,
480
],
[
480,
24,
880
]
],
[
[
36,
24,
659
],
[
659,
24,
880
]
],
[
[
36,
24,
214
],
[
214,
63,
... | [
[
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
... | Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol... |
DB00526 | DB01177 | 1,555 | 77 | [
"DDInter1355",
"DDInter904"
] | Oxaliplatin | Idarubicin | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
1555,
24,
77
]
],
[
[
1555,
24,
739
],
[
739,
23,
77
]
],
[
[
1555,
23,
1247
],
[
1247,
23,
77
]
],
[
[
1555,
24,
823
],
[
823,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole an... |
DB00679 | DB01278 | 684 | 1,021 | [
"DDInter1796",
"DDInter1506"
] | Thioridazine | Pramlintide | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
684,
24,
1021
]
],
[
[
684,
24,
1507
],
[
1507,
24,
1021
]
],
[
[
684,
40,
9
],
[
9,
63,
1021
]
],
[
[
684,
63,
1466
],
[
1466,
... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Thioridazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate i... |
DB01211 | DB08867 | 609 | 807 | [
"DDInter393",
"DDInter1897"
] | Clarithromycin | Ulipristal | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocor... | Minor | 0 | [
[
[
609,
23,
807
]
],
[
[
609,
25,
1135
],
[
1135,
62,
807
]
],
[
[
609,
62,
600
],
[
600,
23,
807
]
],
[
[
609,
63,
723
],
[
723,
2... | [
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ulipristal"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Nalox... | Clarithromycin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may ca... |
DB00539 | DB00872 | 11 | 1,080 | [
"DDInter1837",
"DDInter438"
] | Toremifene | Conivaptan | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Major | 2 | [
[
[
11,
25,
1080
]
],
[
[
11,
6,
8374
],
[
8374,
45,
1080
]
],
[
[
11,
21,
28894
],
[
28894,
60,
1080
]
],
[
[
11,
24,
126
],
[
126,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Conivap... | Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Conivaptan (Compound)
Toremifene (Compound) causes Cardiac failure (Side Effect) and Cardiac failure (Side Effect) is caused by Conivaptan (Compound)
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Warfari... |
DB08931 | DB12130 | 947 | 1,017 | [
"DDInter1600",
"DDInter1094"
] | Riociguat | Lorlatinib | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
947,
24,
1017
]
],
[
[
947,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
947,
63,
888
],
[
888,
24,
1017
]
],
[
[
947,
24,
1450
],
[
1450,
... | [
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen m... |
DB01064 | DB04948 | 1,148 | 1,084 | [
"DDInter987",
"DDInter1083"
] | Isoprenaline | Lofexidine | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
1148,
24,
1084
]
],
[
[
1148,
63,
618
],
[
618,
24,
1084
]
],
[
[
1148,
24,
774
],
[
774,
63,
1084
]
],
[
[
1148,
24,
392
],
[
392,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abarelix"
],
[
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degarel... |
DB00622 | DB01246 | 1,081 | 820 | [
"DDInter1287",
"DDInter45"
] | Nicardipine | Alimemazine | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1081,
24,
820
]
],
[
[
1081,
24,
104
],
[
104,
40,
820
]
],
[
[
1081,
24,
401
],
[
401,
24,
820
]
],
[
[
1081,
6,
8374
],
[
8374,
... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction... |
DB00863 | DB08912 | 1,194 | 1,040 | [
"DDInter1568",
"DDInter462"
] | Ranitidine | Dabrafenib | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1194,
24,
1040
]
],
[
[
1194,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
1194,
18,
5527
],
[
5527,
57,
1040
]
],
[
[
1194,
21,
28900
],
[
28... | [
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Ranitidine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Ranitidine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Ranitidine (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Dabrafenib (Compound)
Ranitidine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compou... |
DB00951 | DB01222 | 1,072 | 617 | [
"DDInter986",
"DDInter246"
] | Isoniazid | Budesonide | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
1072,
24,
617
]
],
[
[
1072,
62,
251
],
[
251,
1,
617
]
],
[
[
1072,
23,
1220
],
[
1220,
1,
617
]
],
[
[
1072,
6,
8374
],
[
8374,
... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betamethasone"
],
[
... | Isoniazid may cause a minor interaction that can limit clinical effects when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Isoniazid may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide (Comp... |
DB00912 | DB06448 | 473 | 171 | [
"DDInter1581",
"DDInter1087"
] | Repaglinide | Lonafarnib | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Moderate | 1 | [
[
[
473,
24,
171
]
],
[
[
473,
24,
222
],
[
222,
23,
171
]
],
[
[
473,
24,
850
],
[
850,
63,
171
]
],
[
[
473,
64,
1347
],
[
1347,
2... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Lonafarnib
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin... |
DB00790 | DB06792 | 664 | 1,606 | [
"DDInter1431",
"DDInter1023"
] | Perindopril | Lanthanum carbonate | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led... | Moderate | 1 | [
[
[
664,
24,
1606
]
],
[
[
664,
40,
610
],
[
610,
24,
1606
]
],
[
[
664,
1,
954
],
[
954,
24,
1606
]
],
[
[
664,
40,
610
],
[
610,
4... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Perindopril",
"{u} (Compound) resembles {v} (Compound)",
"Enalapril"
],
[
"Enalapril",
"{u} may cause ... | Perindopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Perindopril (Compound) resembles Quinapril (Compound) and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Lant... |
DB08899 | DB12332 | 129 | 1,619 | [
"DDInter649",
"DDInter1626"
] | Enzalutamide | Rucaparib | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
129,
24,
1619
]
],
[
[
129,
63,
307
],
[
307,
23,
1619
]
],
[
[
129,
62,
271
],
[
271,
23,
1619
]
],
[
[
129,
25,
1135
],
[
1135,
... | [
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
... | Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegro... |
DB00023 | DB00227 | 305 | 1,463 | [
"DDInter127",
"DDInter1098"
] | Asparaginase Escherichia coli | Lovastatin | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Moderate | 1 | [
[
[
305,
24,
1463
]
],
[
[
305,
24,
681
],
[
681,
1,
1463
]
],
[
[
305,
24,
123
],
[
123,
62,
1463
]
],
[
[
305,
24,
1613
],
[
1613,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Pravastatin and Pravastatin (Compound) resembles Lovastatin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may c... |
DB04845 | DB11932 | 309 | 327 | [
"DDInter1001",
"DDInter3"
] | Ixabepilone | Abametapir (topical) | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
309,
24,
327
]
],
[
[
309,
63,
168
],
[
168,
24,
327
]
],
[
[
309,
24,
283
],
[
283,
63,
327
]
],
[
[
309,
24,
868
],
[
868,
24,... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Ixabepil... |
DB00445 | DB08867 | 322 | 807 | [
"DDInter655",
"DDInter1897"
] | Epirubicin | Ulipristal | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocor... | Moderate | 1 | [
[
[
322,
24,
807
]
],
[
[
322,
63,
600
],
[
600,
23,
807
]
],
[
[
322,
24,
609
],
[
609,
23,
807
]
],
[
[
322,
24,
850
],
[
850,
63,... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ulipristal"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Cl... |
DB01124 | DB12500 | 1,411 | 283 | [
"DDInter1828",
"DDInter714"
] | Tolbutamide | Fedratinib | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1411,
24,
283
]
],
[
[
1411,
63,
1419
],
[
1419,
24,
283
]
],
[
[
1411,
24,
761
],
[
761,
24,
283
]
],
[
[
1411,
64,
600
],
[
600,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagli... |
DB00959 | DB01149 | 1,486 | 851 | [
"DDInter1191",
"DDInter1274"
] | Methylprednisolone | Nefazodone | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Major | 2 | [
[
[
1486,
25,
851
]
],
[
[
1486,
6,
8374
],
[
8374,
45,
851
]
],
[
[
1486,
7,
4759
],
[
4759,
46,
851
]
],
[
[
1486,
21,
28762
],
[
28762,... | [
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nefazodone"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Methylprednisolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nefazodone (Compound)
Methylprednisolone (Compound) upregulates SERPINA3 (Gene) and SERPINA3 (Gene) is upregulated by Nefazodone (Compound)
Methylprednisolone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by ... |
DB11601 | DB11834 | 1,270 | 1,303 | [
"DDInter1889",
"DDInter849"
] | Tuberculin purified protein derivative | Guselkumab | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
1270,
24,
1303
]
],
[
[
1270,
63,
713
],
[
713,
24,
1303
]
],
[
[
1270,
24,
270
],
[
270,
63,
1303
]
],
[
[
1270,
63,
375
],
[
375,
... | [
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases ... | Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Tuberculin purified protein derivative may cause a moderate interactio... |
DB00215 | DB11110 | 1,230 | 603 | [
"DDInter388",
"DDInter1115"
] | Citalopram | Magnesium citrate | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
1230,
24,
603
]
],
[
[
1230,
25,
57
],
[
57,
24,
603
]
],
[
[
1230,
25,
484
],
[
484,
63,
603
]
],
[
[
1230,
24,
477
],
[
477,
2... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Citalopram may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Citalopram may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may ... |
DB00641 | DB08912 | 467 | 1,040 | [
"DDInter1675",
"DDInter462"
] | Simvastatin | Dabrafenib | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
467,
24,
1040
]
],
[
[
467,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
467,
7,
2969
],
[
2969,
46,
1040
]
],
[
[
467,
18,
12411
],
[
12411,
... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Simvastatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Simvastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Simvastatin (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Dabrafenib (Compound)
Simvastatin (Compound) downregulates MYL9 (Gene) and MYL9 (Gene) is upregulated by Dabrafenib (Compound)
Simvastatin (Co... |
DB00176 | DB06822 | 529 | 802 | [
"DDInter770",
"DDInter1812"
] | Fluvoxamine | Tinzaparin | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Moderate | 1 | [
[
[
529,
24,
802
]
],
[
[
529,
25,
222
],
[
222,
24,
802
]
],
[
[
529,
63,
1432
],
[
1432,
25,
802
]
],
[
[
529,
25,
1347
],
[
1347,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutra... | Fluvoxamine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Abciximab and Abciximab may lead... |
DB01166 | DB11642 | 477 | 938 | [
"DDInter379",
"DDInter1480"
] | Cilostazol | Pitolisant | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
477,
24,
938
]
],
[
[
477,
62,
112
],
[
112,
23,
938
]
],
[
[
477,
25,
760
],
[
760,
24,
938
]
],
[
[
477,
24,
28
],
[
28,
24,
... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Cilostazol may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may caus... |
DB00601 | DB11988 | 453 | 270 | [
"DDInter1073",
"DDInter1321"
] | Linezolid | Ocrelizumab | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
453,
24,
270
]
],
[
[
453,
63,
134
],
[
134,
24,
270
]
],
[
[
453,
24,
1096
],
[
1096,
24,
270
]
],
[
[
453,
25,
1053
],
[
1053,
... | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
... | Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid an... |
DB00748 | DB09076 | 662 | 1,116 | [
"DDInter297",
"DDInter1899"
] | Carbinoxamine | Umeclidinium | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
662,
24,
1116
]
],
[
[
662,
35,
849
],
[
849,
24,
1116
]
],
[
[
662,
63,
1300
],
[
1300,
24,
1116
]
],
[
[
662,
24,
1511
],
[
1511,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when... | Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Carbinoxamine may cause a moderate interaction... |
DB00390 | DB11901 | 1,252 | 913 | [
"DDInter554",
"DDInter107"
] | Digoxin | Apalutamide | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1252,
24,
913
]
],
[
[
1252,
25,
609
],
[
609,
24,
913
]
],
[
[
1252,
24,
1320
],
[
1320,
63,
913
]
],
[
[
1252,
24,
1468
],
[
1468,
... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Digoxin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromy... | Digoxin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.